Benjamin F. Edwards & Company, Inc. Seagen Inc. Transaction History

Benjamin F. Edwards & Company, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	SELL	$187.64 - $206.25 $1,125 - $1,237	-6 Reduced 16.67%	30 $6,000
Q3 2022 Oct 28, 2022	SELL	$135.27 - $180.11 $43,556 - $57,995	-322 Reduced 89.94%	36 $5,000
Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $61,912 - $102,038	-569 Reduced 61.38%	358 $63,000
Q1 2022 May 04, 2022	SELL	$119.61 - $157.85 $41,743 - $55,089	-349 Reduced 27.35%	927 $134,000
Q4 2021 Feb 07, 2022	BUY	$142.57 - $190.86 $45,337 - $60,693	318 Added 33.19%	1,276 $197,000
Q3 2021 Nov 02, 2021	BUY	$142.45 - $169.82 $6,410 - $7,641	45 Added 4.93%	958 $163,000
Q2 2021 Aug 11, 2021	BUY	$135.08 - $161.1 $69,296 - $82,644	513 Added 128.25%	913 $144,000
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $13,751 - $19,080	-100 Reduced 20.0%	400 $56,000
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $82,315 - $105,965	500 New	500 $88,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.